Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7 EUR | +1.45% | +1.76% | -65.69% |
May. 14 | Biophytis unveils design for obesity study | CF |
May. 14 | Biophytis SA Announces the Design of its Phase 2 OBA Clinical Study in Obesity | CI |
Sales 2024 * | - | Sales 2025 * | 4.8M 5.2M | Capitalization | 1.97M 2.14M |
---|---|---|---|---|---|
Net income 2024 * | -19M -20.6M | Net income 2025 * | -16M -17.34M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.41 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 22 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 40.58% |
1 day | +1.45% | ||
1 week | +1.76% | ||
Current month | +1.45% | ||
1 month | -11.39% | ||
3 months | -58.33% | ||
6 months | -68.75% | ||
Current year | -65.69% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-03 | 0.7 | +1.45% | 5 755 |
24-05-31 | 0.69 | -1.41% | 18,656 |
24-05-30 | 0.6999 | -4.12% | 43,018 |
24-05-29 | 0.73 | 0.00% | 10,235 |
24-05-28 | 0.73 | +6.12% | 19,688 |
Real-time Euronext Paris, June 03, 2024 at 07:19 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-65.69% | 2.14M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.61% | 21.96B | |
-9.16% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- ALBPS Stock